Abstract: The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.

Abstract: The present invention relates to a method for identifying frameshift mutations in coding nucleic acid sequences.

Abstract: The invention relates to nucleic acid modifications for a directed expression modulation by the targeted insertion or removal of CpG dinucleotides. The invention also relates to modified nucleic acids and expression vectors.

Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.

Abstract: The invention relates to vector constructs for an HIV-specific gene therapy. The expression of transgenes is coupled with an infection of the cell with HIV while the transcription of the transgene is controlled by a transcription control region derived from HIV. In addition, the transgene is improved with regard to RNA stability and expression efficiency by modifying the nucleotide sequence.

Abstract: The present invention relates to reading-frame-correct fragment libraries, methods for their production, and the use of the fragment libraries for selection of functional polypeptide variants with improved properties.

Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.

Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.

Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.

Abstract: The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.

Abstract: The present invention relates to a method for identifying frameshift mutations in coding nucleic acid sequences.

Abstract: The present invention relates to methods for producing variants of proteins which have improved properties in comparison with the initial protein, the variants being obtained with the aid of an in vivo evolution method.

Abstract: The present invention relates to the production of variants of a protein in an in vitro evolution method, comprising the steps: (A) provision of an in vitro expression system comprising (i) a nucleic acid sequence S which codes for a protein Y which is to be varied, (ii) a target molecule X which is able to bind to the protein Y and/or at least one variant Y? thereof, (iii) an RNA polymerase (Pol) which is able to transcribe the nucleic acid sequence S, (iv) a reverse transcriptase (RT) which is capable of reverse transcription of transcripts of the nucleic acid sequence S, where either the target molecule X is coupled to Pol and the protein Y is coupled to RT, or the target molecule X is coupled to RT and the protein Y is coupled to Pol, (B)incubation of the in vitro expression system from (A) under conditions which enable transcription, reverse transcription and translation to form variants Y? of the protein Y and nucleic acid sequences S? coding therefor, and which favor the formation of variants Y? with i

Abstract: The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.

Abstract: The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, vaccines or diagnostic substances, preferably for the treatment, prevention or diagnostic of HIV infections.

Abstract: The present invention refers to a polynucleotide comprising the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3 or the fragment or derivative thereof, or a polynucleotide hybridizing with the nucleic acid sequence as depicted in SEQ ID NO:1, 2 or 3. The present invention further refers to polypeptides encoded by the nucleic acid sequence or the fragment or derivative thereof as depicted in SEQ ID NO:1, 2 or 3. The polynucleotides and polypeptides may be used as medicaments, vaccines or diagnostic substances, preferably for the treatment, prevention or diagnostic of HIV infections.